Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Compass Therapeutics (CMPX) shares rose after Craig-Hallum initiated coverage with a Buy rating and a $15.00 price target, citing confidence in the company’s bispecific antibody strategy and a near-term commercial opportunity for lead candidate tovecimig in second-line biliary tract cancer. The firm also highlighted early-stage programs positioned …
Two men were jailed after being convicted of plotting an Islamic State-inspired assault intended to kill large numbers of Jewish people in England. Prosecutors argued the plan, which involved automatic firearms, could have resulted in casualties exceeding those from a December mass shooting in Sydney. A judge imposed minimum terms of 37 and 26 year…
Canaccord Genuity reduced its price target on CVRx Inc to $10.00 from $11.00 but maintained a Buy rating, citing lower valuation multiples within the small-cap medical technology peer group. CVRx reported fourth-quarter 2025 revenue of $16.0 million, beating Canaccord and consensus estimates and aligning with the company’s own guidance range. The c…
Major brokerages issued contrasting views on Rivian on Friday. Deutsche Bank raised its rating to Buy and lifted its price target, citing signs of an improving trajectory, better vehicle costs and a clearer 2026 outlook. UBS moved to Neutral from Sell, saying the company’s path to scale and profitability remains uncertain amid cash burn and executi…
Apellis Pharmaceuticals executive Mark Jeffrey DeLong sold 368 shares of company stock on February 11, 2026, for $8,152 to cover tax withholding tied to restricted stock units released the prior day. The transaction leaves DeLong with 114,591 directly held shares. The sale coincides with a corporate pre-announcement of $689 million in fourth-quarte…
Coherus BioSciences Inc. (CHRS) saw its shares fall sharply in premarket trading after the company priced a public offering of 28.6 million shares at $1.75 apiece, a meaningful markdown from the prior close. The offering is expected to generate roughly $50.1 million in gross proceeds before underwriting fees, and includes a 30-day option for underw…
Canaccord Genuity reduced its 12-month price target for DexCom to $95 from $99 on Friday but maintained a Buy rating. The adjustment follows a quarter that beat revenue expectations and continues a multiyear growth trend, with analysts citing product iteration, margin expansion potential from the G7 sensor, and several pending catalysts that could …
Goldman Sachs CEO David Solomon said he had "reluctantly accepted" the resignation of Chief Legal Officer Kathy Ruemmler and emphasized his respect for her decision. The exit follows Justice Department documents indicating Ruemmler accepted gifts from Jeffrey Epstein and counseled him on responding to media inquiries about his crimes. Her departure…
The Federal Reserve is expected to nominate Randall Guynn, a long-time Wall Street lawyer and former Davis Polk partner, as director of supervision and regulation. Guynn, who has advised Fed Vice Chair for Supervision Michelle Bowman since May 2025, would replace Michael Gibson and report to Bowman while overseeing proposed changes to the Fed's sup…
Amkor Technology's stock slid in premarket trading after the company's largest shareholder, the Kim Family, sold 10 million shares in a secondary offering priced at $48.75 per share. The transaction, executed through 915 Investments, LP, included a 30-day option for an additional 1.5 million shares, leaves the family with over 49% ownership, and im…
TKO Group is increasingly a cash-flow story. After a string of rights monetization wins and a dividend bump plus buyback activity, the business prints meaningful free cash flow ($979M) and trades at attractive enterprise multiples (EV/EBITDA 12.8) relative to its growth optionality. This trade idea targets a measured long into that cash conversion …
OKYO Pharma Limited (NASDAQ:OKYO) announced a $20 million public offering of ordinary shares under an underwriting agreement with Piper Sandler & Co., prompting a 24% decline in Friday premarket trading. The offering covers 10,815,000 shares at $1.85 each, with a 30-day option for an additional 1,622,250 shares at the same price. Proceeds are earma…
Adobe has been slammed with the broader software sell-off tied to AI fears, but the company still generates nearly $10B in free cash flow, posts extremely high returns on capital, and trades at a single-digit-ish free cash flow multiple. This idea lays out a mid-term swing trade: entry at the current price, a clear stop under the recent low, and a …
BMO Capital Markets downgraded Dollar Tree to Underperform from Market Perform and trimmed its price target to $95, saying the stock's valuation and earnings outlook look stretched given gaps in digital strategy and risks to margin expansion. The bank applied a lower multiple to a below-consensus earnings forecast for fiscal 2027 and flagged potent…
Nebius (NBIS) is positioned at the center of the AI compute buildout. A credible jump in annual run-rate to the low billions by year-end and improving GPU-as-a-Service economics create a pathway to $180/share. This trade idea lays out an entry, stop, and targets with a long-term (180 trading days) horizon while calling out execution, margin, and ma…
Remy Cointreau is a high-quality luxury spirits franchise that has struggled with cyclical demand and FX pressure. The underlying brand strength and margin leverage argue for a long position aimed at 2026 realization, but this trade requires patience and a clear stop to manage execution risk.
Tri Pointe Homes agreed to be acquired by Japan’s Sumitomo Forestry in an all-cash transaction valued at about $4.5 billion. The $47.00 per-share offer represents a notable premium to recent trading levels and drove a sharp premarket rally in Tri Pointe shares. The transaction, expected to close in the second quarter of 2026 subject to shareholder …
U.S. consumer prices rose modestly in January, with the Consumer Price Index increasing 0.2% from December and 2.4% from a year earlier, slightly under economists' expectations. The delayed release did not change the view among many market participants that the Federal Reserve remains positioned to lower interest rates later this year, though under…
PJM Interconnection's recent proposal to manage growing electricity demand from data centers includes options for large users to supply their own new generation or to operate under a connect-and-manage regime that limits usage ahead of other emergency actions. Analysts say the plan - alongside a potential backstop capacity auction - could accelerat…
First BanCorp director Roberto R. Herencia sold 4,723 shares on February 11, 2026, for $22.633 per share, totaling $106,895. The transaction was disclosed on a Form 4 filing. The sale comes as the stock trades close to its 52-week high and after the bank reported slightly better-than-expected fourth-quarter 2025 results and unveiled a CFO retiremen…
Regulatory disclosures for Thursday, February 12, 2026 showed no material insider buying or selling. While the absence of significant transactions provides limited new signals for market participants, tracking insider activity remains a useful component of investment research because purchases and sales can reflect executives' and major shareholder…
D.A. Davidson launched coverage of AMD, Intel, Broadcom and Taiwan Semiconductor Manufacturing Co., assigning Neutral ratings to AMD, Intel and Broadcom while naming TSMC the only Buy. Analyst Gil Luria pointed to widening competitive differences, warning of customer-led shifts in AI silicon demand that could pressure some suppliers while praising …
Bank of England Chief Economist Huw Pill told a Santander Bank event in London that it is becoming harder to gauge how much monetary policy is suppressing demand. While he described the disinflation process as intact but incomplete, Pill said wage settlements remain elevated and that underlying inflation would be about 2.5% after removing a half pe…
Guggenheim has downgraded Itron from Buy to Neutral and removed its prior $155 price target after revising the company's near-term growth outlook. The firm reduced revenue and EBITDA estimates for 2026 and 2027, citing lower backlog coverage entering 2026 and the expected operating cost impact from recent acquisitions. Itron continues to roll out p…
Jefferies downgraded Ormat Technologies (NYSE: ORA) from Buy to Hold even as it raised its price target to $130 from $125, saying much of the company’s upside from enhanced geothermal systems and data-center agreements appears priced in. The research house flagged several near- and medium-term metrics for investors to watch, while other analysts re…
